Ingenuity Extends Pathway Analysis Software Deal With Merck

Feb 13, 2007

NEW YORK (GenomeWeb News) — Ingenuity Systems today said it has extended a licensing agreement with Merck that allows the drug maker to continue using its Ingenuity Pathways Analysis Software.

Under the terms of the “multi-year” agreement, Merck will continue to use the IPA software for research in “multiple therapeutic areas,” Ingenuity said.

The original agreement was signed in 2004, but the company did not say when the extended licensing contract will expire.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Scan

Here We Are Again

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

In the Pink

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

All Tied Up in a Bow

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

This Week in PNAS

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.

Jun

12

Featured Webinar

Bridging the Gap Between Testing and Treatment in Precision Oncology

This webinar will highlight a comprehensive end-to-end solution for precision care in oncology, comprising sample acquisition through to sequencing and analysis, treatment recommendations, and follow-through.

Main menu